carbamates has been researched along with pl 100 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dandache, S; Parkin, N; Schapiro, JM; Sévigny, G; Stranix, BR; Wainberg, MA; Wu, JJ; Yelle, J | 1 |
| Allison, TJ; Coburn, CA; Dandache, S; Holloway, MK; Oliveira, M; Panchal, C; Stranix, BR; Vacca, JP; Wainberg, MA; Wu, JJ | 1 |
| Asahchop, EL; Brenner, BG; Dandache, S; Martinez-Cajas, JL; Moisi, D; Ntemgwa, M; Oliveira, M; Stranix, B; Toni, Td; Tremblay, CL; Wainberg, MA | 1 |
| Asahchop, EL; Brenner, BG; Martinez-Cajas, JL; Moisi, D; Oliveira, M; Quashie, PK; Tremblay, CL; Wainberg, MA | 1 |
4 other study(ies) available for carbamates and pl 100
| Article | Year |
|---|---|
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Cell Survival; Drug Resistance, Viral; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Mutation; Phenotype; Sulfonamides; Viral Proteins | 2007 |
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Topics: Carbamates; Catalytic Domain; Cells, Cultured; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Models, Molecular; Mutagenesis, Site-Directed; Mutation, Missense; Protein Structure, Tertiary; Sulfonamides | 2008 |
Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes.
Topics: Amino Acid Substitution; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation, Missense; Sulfonamides | 2010 |
In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
Topics: Carbamates; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Structure-Activity Relationship; Sulfonamides | 2013 |